What is HC Wainwright's Estimate for NeuroPace Q1 Earnings?

Key Points

• HC Wainwright projects that NeuroPace will report a Q1 2026 earnings per share of ($0.23), maintaining a "Buy" rating with an $18.00 price target.
• In its latest quarterly results, NeuroPace missed expectations with an EPS of ($0.26), although revenue reached $23.52 million, surpassing forecasts.
• Institutional investors hold 78.83% of NeuroPace stock, with significant acquisitions reported from firms like First Light Asset Management and Deutsche Bank during the first quarter.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for NeuroPace in a report released on Thursday, August 14th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.23) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace's Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.24) EPS and Q4 2026 earnings at ($0.24) EPS.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. The business had revenue of $23.52 million for the quarter, compared to analysts' expectations of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS.

Several other equities research analysts have also commented on the stock. Wells Fargo & Company reduced their price target on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. Zacks Research downgraded shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.60.

NeuroPace Stock Up 5.0%

Shares of NASDAQ:NPCE traded up $0.41 during trading hours on Friday, hitting $8.66. The company's stock had a trading volume of 506,772 shares, compared to its average volume of 277,205. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.98. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. The company has a market capitalization of $286.48 million, a price-to-earnings ratio of -10.31 and a beta of 1.89. The firm's fifty day moving average price is $9.72 and its 200 day moving average price is $11.64.

Institutional Investors Weigh In On NeuroPace

A number of large investors have recently modified their holdings of the business. Lazard Asset Management LLC grew its stake in shares of NeuroPace by 2,445.5% during the second quarter. Lazard Asset Management LLC now owns 78,885 shares of the company's stock worth $878,000 after acquiring an additional 75,786 shares during the last quarter. Engineers Gate Manager LP grew its stake in shares of NeuroPace by 33.6% during the second quarter. Engineers Gate Manager LP now owns 13,609 shares of the company's stock worth $152,000 after acquiring an additional 3,420 shares during the last quarter. PDT Partners LLC purchased a new stake in shares of NeuroPace during the second quarter worth about $264,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of NeuroPace by 60.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,160 shares of the company's stock worth $147,000 after acquiring an additional 4,972 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in NeuroPace by 74.7% in the second quarter. Qube Research & Technologies Ltd now owns 112,637 shares of the company's stock valued at $1,255,000 after buying an additional 48,175 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.